{
    "Case ID": "046861",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent infringement dispute over pharmaceutical product (lisinopril)"
    ],
    "Legal_Issue": [
        "Whether Apotex can claim noninfringement under s. 56 of the Patent Act to avoid prohibition of NOC issuance"
    ],
    "Governing_Law": [
        "Patent Act, s. 56"
    ],
    "Procedural_Stage": [
        "Judicial review application under Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Evidence_Assessment": [
        "Apotex acquired lisinopril before the '350 patent but not before the '351 patent's novel use was patented"
    ],
    "Decision_Outcome": [
        "Apotex cannot rely on s. 56 immunity for the '351 patent; prohibition on NOC issuance upheld"
    ],
    "Burden_of_Proof": [
        "On Apotex to establish entitlement to s. 56 immunity"
    ],
    "Credibility_Factor": [],
    "Legal_Rule": [
        "s. 56 of the Patent Act provides immunity from liability for acts prior to patent grant but does not constitute a finding of noninfringement"
    ],
    "Standard_of_Review": [
        "Reasonableness or correctness, as applicable to administrative decisions under judicial review"
    ],
    "Procedural_Issue": [
        "Interpretation and application of s. 56 in the context of NOC regulations"
    ],
    "Grounds_for_Claim": [
        "Zeneca alleged infringement of both '350 and '351 patents by Apotex's submission for NOC"
    ],
    "Outcome_on_Merits": [
        "Claim partially upheld: s. 56 applies only to '350 patent, not '351; NOC prohibited until both patents expire"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "Minister prohibited from issuing NOC to Apotex"
    ],
    "Review_Standard": [
        "Standard applicable to judicial review of Minister’s decision under NOC Regulations"
    ],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Timing of Apotex's acquisition of lisinopril relative to the grant dates of the '350 and '351 patents"
    ],
    "Legal_Framework": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Applicant_Challenge": [
        "Apotex challenged the prohibition on NOC based on s. 56 immunity"
    ],
    "Court_Result": [
        "Apotex unsuccessful in claiming s. 56 protection for '351 patent"
    ],
    "Legal_Rule_Source": [
        "Patent Act, s. 56"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Apotex claimed immunity under s. 56 of the Patent Act"
    ],
    "Evidence_Type": [
        "Documentary evidence regarding patent dates and product development timeline"
    ],
    "Remedy_Requested": [
        "Prevention of NOC issuance to Apotex"
    ],
    "Outcome": [
        "NOC issuance prohibited until expiration of both patents"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Interim injunction or prohibition order preventing NOC issuance"
    ],
    "Resolution_Mechanism": [
        "Judicial review"
    ],
    "Legal_Provision": [
        "Patent Act, s. 56"
    ],
    "Authority": [
        "Federal Court"
    ],
    "Claimant_Status": [
        "Zeneca as patent holder and innovator"
    ],
    "Legal_Provision_Cited": [
        "s. 56 of the Patent Act"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Alleged infringement of '351 patent despite pre-patent activity covered by s. 56 for '350 patent"
    ],
    "Applicable_Process": [
        "Judicial review under NOC Regulations"
    ],
    "Outcome_of_Review": [
        "Application allowed in part; prohibition maintained"
    ],
    "Pending_Relief_or_Application": [
        "Application for judicial review of Minister’s decision"
    ],
    "Jurisdiction": [
        "Federal jurisdiction – intellectual property, patents"
    ],
    "Governing_Rule": [
        "s. 56 of the Patent Act"
    ]
}